October 7th, 2021 WXXI’s Randy Gorbman reports on Cognivue, Inc. with an interview with Cognivue’s President and CEO, Tom O’Neill. Read & Listen 

Geneva, 21 September 2021 – The Davos Alzheimer’s Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease. DAC announced today it has successfully completed financing of its foundational phase and has launched…

ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…

Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability; Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods ROCHESTER, N.Y., June 25, 2021—Neuroscience company…

Cognivue, Inc. and the American Institute of Balance Announce Inaugural Thought Leader Summit June 25-26, 2021 Audiology and otolaryngology leaders will discuss the industry’s role as part of a standard of care…

Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee The Alliance seeks to transform and improve the complex health and long-term care systems for individuals at risk for and…

ROCHESTER, N.Y., May 12, 2021—Neuroscience company Cognivue, Inc. recently conducted a virtual national symposium to better define and establish a cognitive health care continuum that serves a diverse and growing at-risk population….

VICTOR, N.Y. (WROC)- April 27th, 2021: Top Stories

Cognivue to Participate in Major Clinical Study with Global Alzheimer’s Platform   First FDA-cleared computerized test of cognitive function will be evaluated in the Bio-Hermes study; seeks to improve identification and screening…

Dr. Fred Ma addresses the COVID-19 pandemic and the role of cognitive testing. Cognivue CMO Newsletter, Fall 2020